Vincerx Pharma (VINC) Stock Forecast, Price Target & Predictions
VINC Stock Forecast
Vincerx Pharma stock forecast is as follows: an average price target of $4.00 (represents a 467.94% upside from VINC’s last price of $0.70) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VINC Price Target
The average price target for Vincerx Pharma (VINC) is $4.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 467.94% upside from VINC's last price of $0.70.
VINC Analyst Ratings
According to 2 Wall Street analysts, Vincerx Pharma's rating consensus is 'Buy'. The analyst rating breakdown for VINC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vincerx Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2022 | Matthew Barcus | Chardan Capital | $4.00 | $1.98 | 102.02% | 467.94% |
The latest Vincerx Pharma stock forecast, released on Jun 07, 2022 by Matthew Barcus from Chardan Capital, set a price target of $4.00, which represents a 102.02% increase from the stock price at the time of the forecast ($1.98), and a 467.94% increase from VINC last price ($0.70).
Vincerx Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.70 | $0.70 | $0.70 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Vincerx Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vincerx Pharma's last price of $0.70. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 17, 2022 | Chardan Capital | Buy | Buy | Hold |
| Jun 07, 2022 | B. Riley Securities | Buy | Buy | Hold |
Vincerx Pharma's last stock rating was published by Chardan Capital on Nov 17, 2022. The company gave VINC a "Buy" rating, the same as its previous rate.
Vincerx Pharma Financial Forecast
Vincerx Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vincerx Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VINC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vincerx Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VINC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vincerx Pharma's previous annual EBITDA (undefined) of $NaN.
Vincerx Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-8.05M | $-9.20M | $-8.82M | $-8.43M | $-7.16M | $-8.31M | $-7.86M |
| High Forecast | $-8.05M | $-9.20M | $-8.82M | $-8.43M | $-7.16M | $-8.31M | $-7.86M |
| Low Forecast | $-8.05M | $-9.20M | $-8.82M | $-8.43M | $-7.16M | $-8.31M | $-7.86M |
| Surprise % | - | - | - | - | - | - | - |
Vincerx Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VINC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vincerx Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vincerx Pharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VINC last annual SG&A of $NaN (undefined).
Vincerx Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.21 | $-0.24 | $-0.23 | $-0.22 | $-0.19 | $-0.22 | $-0.20 |
| High Forecast | $-0.21 | $-0.24 | $-0.23 | $-0.22 | $-0.19 | $-0.22 | $-0.20 |
| Low Forecast | $-0.21 | $-0.24 | $-0.23 | $-0.22 | $-0.19 | $-0.22 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vincerx Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VINC previous annual EPS of $NaN (undefined).
Vincerx Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CHRS | Coherus BioSciences | $1.30 | $9.00 | 592.31% | Hold |
| PCSA | Processa Pharmaceuticals | $1.34 | $9.00 | 571.64% | Buy |
| VINC | Vincerx Pharma | $0.70 | $4.00 | 471.43% | Buy |
| LVTX | LAVA Therapeutics | $1.72 | $6.00 | 248.84% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| BCAB | BioAtla | $1.81 | $5.00 | 176.24% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
VINC Forecast FAQ
Is Vincerx Pharma a good buy?
Yes, according to 2 Wall Street analysts, Vincerx Pharma (VINC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VINC's total ratings.
What is VINC's price target?
Vincerx Pharma (VINC) average price target is $4 with a range of $4 to $4, implying a 467.94% from its last price of $0.704. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vincerx Pharma stock go up soon?
According to Wall Street analysts' prediction for VINC stock, the company can go up by 467.94% (from the last price of $0.704 to the average price target of $4), up by 467.94% based on the highest stock price target, and up by 467.94% based on the lowest stock price target.
Can Vincerx Pharma stock reach $1?
VINC's average twelve months analyst stock price target of $4 supports the claim that Vincerx Pharma can reach $1 in the near future.
What are Vincerx Pharma's analysts' financial forecasts?
Vincerx Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-23.323M (high $-23.323M, low $-23.323M), average SG&A $0 (high $0, low $0), and average EPS is $-0.608 (high $-0.608, low $-0.608). VINC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.505M (high $-34.505M, low $-34.505M), average SG&A $0 (high $0, low $0), and average EPS is $-0.9 (high $-0.9, low $-0.9).